Last reviewed · How we verify

NCT04066283

Effects of Aging and Gender-Affirming Hormone Therapy on Vascular Endothelial Function and Metabolic Profiles in Transgender Women

Completed Last updated 19 September 2024
What this trial tests

trial testing No intervention in Transgender in 29 participants. Completed in 31 December 2023.

Timeline
17 April 2019
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusCompleted
Study typeOBSERVATIONAL
Enrollment29
Start date17 April 2019
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 75, any sex, with Transgender or Gender Identity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in younger versus older transgender women (people who were assigned male at birth but whose gender identity is female). Data will also be compared to those from cisgender women and men.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Transgender

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04066283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing